Journal for ImmunoTherapy of Cancer (Nov 2021)

143 Mesothelin (MSLN) targeting allogeneic CAR T cells engineered to overcome tumor immunosuppressive microenvironment

Agnes Gouble,
Roman Galetto,
Cécile Schiffer-Mannioui,
Sophie Leduc,
Isabelle Chion-Sotinel,
Diane le Clerre,
Valérie Guyot,
Marco Rotondi

Affiliations

Agnes Gouble: Aff1 Cellectis Therapeutics Paris France
Roman Galetto: Aff1 Cellectis Therapeutics Paris France
Cécile Schiffer-Mannioui: Aff1 Cellectis Therapeutics Paris France
Sophie Leduc: Cellectis SA, Paris, France
Isabelle Chion-Sotinel: Cellectis SA, Paris, France
Diane le Clerre: Cellectis SA, Paris, France
Valérie Guyot: Cellectis SA, Paris, France
Marco Rotondi: Cellectis SA, Paris, France

DOI: https://doi.org/10.1136/jitc-2021-SITC2021.143
Journal volume & issue: Vol. 9, no. Suppl 2

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal